Literature DB >> 12652152

Problems, interventions and complications in long-term oral anticoagulation therapy.

Claudia Stöllberger1, Josef Finsterer, Thomas Länger, Barbara Schneider, Cornelius Wehinger, Pierre Hopmeier, Jörg Slany.   

Abstract

BACKGROUND: If problems, interventions and complications occurring during oral anticoagulation (OAC) are related with age, indication for OAC, hypertension, diabetes, previous stroke, and number of additional drugs.
MATERIAL AND METHODS: Clinical characteristics, additional drugs, problems, interventions and complications of outpatients whose OAC was controlled between two years were registered. Potential gastrointestinal and urologic bleeding sources were eliminated prior to initiation of OAC. Five-hundred-seventy-nine patients (mean age 65 years, 44% female) were observed for 590 patient-years.
RESULTS: Medical problems occurred in 352/100 patient-years (% p-y), organisational problems in 276% p-y, interventions in 636% p-y and complications in 13.8% p-y. Patients >65 years had less organisational problems (254 vs. 302% p-y, p = 0.0092) and interventions (574 vs. 713% p-y, p = 0.0003) than patients < or =65 years. The 35 patients with heart valve prosthesis had more life-threatening and fatal complications (12% p-y) than the 360 patients with atrial fibrillation (1.0% p-y), 128 patients with venous thromboembolism or 56 patients with other indications (0.0% p-y, p = 0.0024). Problems, interventions and complications were not related with hypertension (n = 297), diabetes (n = 97) or previous stroke (n = 90). Patients with >3 additional drugs/day had a higher complication rate than patients with < or =3 drugs/day (21 vs. 8.7% p-y, p = 0.0238). Patients with complications had more headache (27 vs. 20% p-y, p = 0.0036), chest pain (45 vs. 27% p-y, p = 0.0150), abdominal pain (25 vs. 15% p-y, p = 0.0350) and pain in the limbs (55 vs. 42% p-y, p = 0.0044) than patients without complications.
CONCLUSIONS: By careful monitoring, eliminating potential bleeding sources, treating pain adequately and minimizing additional drugs the complications of OAC can be kept low.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12652152     DOI: 10.1023/a:1022070406307

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  37 in total

1.  Warfarin use among patients with atrial fibrillation.

Authors:  L M Brass; H M Krumholz; J M Scinto; M Radford
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

2.  Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.

Authors:  A S Go; E M Hylek; K A Phillips; L H Borowsky; L E Henault; Y Chang; J V Selby; D E Singer
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

3.  Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort.

Authors:  F H Steffensen; K Kristensen; E Ejlersen; J F Dahlerup; H T Sørensen
Journal:  J Intern Med       Date:  1997-12       Impact factor: 8.989

4.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

5.  Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients.

Authors:  J Launbjerg; H Egeblad; J Heaf; N H Nielsen; A M Fugleholm; K Ladefoged
Journal:  J Intern Med       Date:  1991-04       Impact factor: 8.989

6.  Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.

Authors:  G W Albers; J M Yim; K M Belew; N Bittar; C R Hattemer; B G Phillips; S Kemp; E A Hall; D J Morton; P H Vlasses
Journal:  Arch Intern Med       Date:  1996-11-11

7.  Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.

Authors:  R J Beyth; L M Quinn; C S Landefeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

8.  Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics.

Authors:  R H White; T McKittrick; J Takakuwa; C Callahan; M McDonell; S Fihn
Journal:  Arch Intern Med       Date:  1996-06-10

Review 9.  Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.

Authors:  R G Hart; B S Boop; D C Anderson
Journal:  Stroke       Date:  1995-08       Impact factor: 7.914

10.  Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota.

Authors:  M J Gitter; T M Jaeger; T M Petterson; B J Gersh; M D Silverstein
Journal:  Mayo Clin Proc       Date:  1995-08       Impact factor: 7.616

View more
  1 in total

1.  Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.

Authors:  Anja Kaeberich; Iris Reindl; Uwe Raaz; Lars Maegdefessel; Alexander Vogt; Torsten Linde; Ulrich Steinseifer; Elisabeth Perzborn; Baerbel Hauroeder; Michael Buerke; Karl Werdan; Axel Schlitt
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.